<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531515</url>
  </required_header>
  <id_info>
    <org_study_id>2018-26-MD-EXP</org_study_id>
    <nct_id>NCT03531515</nct_id>
  </id_info>
  <brief_title>Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients</brief_title>
  <official_title>Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjay Gandhi Postgraduate Institute of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanjay Gandhi Postgraduate Institute of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reactive or secondary thrombocytosis is defined as abnormally high platelet count (≥4,50,000&#xD;
      platelets per micro-liter) in the absence of chronic myeloproliferative disease. In&#xD;
      critically ill patients reactive thrombocytosis is not uncommon during recovery phase and an&#xD;
      association has been seen with poor outcome and increased risk of subsequent VTE. However,&#xD;
      not all patients with infection respond with thrombocytosis. No study has enumerated the risk&#xD;
      factors or predictors of reactive thrombocytosis in critically ill septic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients admitted to intensive care unit of the department of Critical Care Medicine&#xD;
      during one year period will be screened for possible inclusion in this study. In this&#xD;
      prospective observational study, demographic and clinical characteristics of all ICU patients&#xD;
      who fulfill inclusion criteria will be collected along with relevant laboratory tests done&#xD;
      for patient management routinely. ICU prognostication scores, i.e., Acute Physiologic and&#xD;
      Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA)&#xD;
      score will also be recorded. ICU survivors will be followed up in their routine ICU follow up&#xD;
      clinic visits.&#xD;
&#xD;
      Sample size was estimated at 10% incidence rate of reactive thrombocytes, two sided 95%&#xD;
      confidence interval and 4.5% margin of error of the incidence rate, sample size came out to&#xD;
      be 171. Finally in this study investigators have targeted to include at least 180&#xD;
      participants. Sample size was estimated using software power analysis and sample size, 2008&#xD;
      (PASS-8).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Reactive or secondary thrombocytosis in critically ill septic patients</measure>
    <time_frame>From date of inclusion until the date of thrombocytosis or date of ICU discharge (death or alive), whichever came first, assessed up to 3 months</time_frame>
    <description>Reactive or secondary thrombocytosis (≥4,50,000 platelets per micro-liter) due to the sepsis</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sepsis</condition>
  <condition>Thrombocytosis</condition>
  <condition>Critically Ill</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All adult (≥18 years) ICU patients with the diagnosis of sepsis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult (≥18 years) ICU patients with the diagnosis of sepsis will be considered.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  H/O Malignancy&#xD;
&#xD;
          -  Thrombocytosis at admission&#xD;
&#xD;
          -  Primary thrombocytosis&#xD;
&#xD;
          -  Post-splenectomy&#xD;
&#xD;
          -  Chronic inflammatory disease (e.g. Connective tissue disorders, IBD, temporal&#xD;
             arteritis)&#xD;
&#xD;
          -  Known immunosupressive condition&#xD;
&#xD;
          -  Chronic infectious diseases (e.g. tuberculosis, chronic pneumonitis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohan Gurjar, MD, PDCC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohan Gurjar, MD, PDCC</last_name>
    <phone>915222495403</phone>
    <email>m.gurjar@rediffmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monalisa Nayak, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, SGPGIMS</name>
      <address>
        <city>Lucknow</city>
        <state>UP</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohan Gurjar, MD, PDCC</last_name>
      <phone>915222495403</phone>
      <email>m.gurjar@rediffmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Arvind K Baronia, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sanjay Gandhi Postgraduate Institute of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mohan Gurjar</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

